Aventis Pharma (Frankfurt, Germany)1998/1999 Successful registration of ARAVA in US and Europe. Ground member of Aventis team for the FDA-advisory board meeting.1997-1999 Setting up eADMET screeningNovartis Pharma (Basel, Switzerland):1999-2000 Reorganisation and efficient management of ADME unit (75 FTEs), strong increase of efficacy (>100%). Implementation of ADMET screening and profiling for discovery support.1999 Team leader for cross functional pharma initiativefor safety assessment for compound evaluation conc. INDs. Team introduced new procedure: SATs (Cross Functional Expert Safety Assessment Teams).2000 Representative for DMPK/Toxicology in overall company team for redefining research strategy. The team was rewarded for its accomplishments.1999/2000/2001/2002/2003/2004/2005 Successful registration of numerous drugs (Gliveec, Myfortic, Zoledronate, Zelmac, Everolimus, Pimecrolimus, ERL080, Exjade, Aliskiren). Responsible for registration package concerning ADME/DMPK. Awarded several times for achievements.2005/2006 Leading global initiative to establish career ladders for Toxicology/Pathology and DMPK. Astrazenca (Alderly Edge, UK):2006/2007 Aligning DMPK models across discovery and development DMPK function. 2006/2007 Creating transporter team, outsourcing team and biomarker group2006/2007 Establishing and implementing DMPK risk matrix for evaluation of2008 : Implementation of numerous new models in transporter and DDI areaDevelopment of global (6 sites) ADME strategy as discipline leaderSpecialties: Profound expertise of the overall pharmaceutical development process, metabolism, drug/drug interactions, transporter, ADME, DMPK and its strategic aspects. Managing budget, personell (20-80 FTEs). Good experience in post-merger activities, setting and implementing strategic goals. Direct experience with regulatory filings and correspondence with regulatory bodies.